The effect of vulvar lichen sclerosus on quality of life and sexual functioning

2010 ◽  
Vol 31 (4) ◽  
pp. 279-284 ◽  
Author(s):  
Hedwig P Van De Nieuwenhof ◽  
Kim A. P. Meeuwis ◽  
Theodoor E. Nieboer ◽  
Marianne C. M. Vergeer ◽  
Leon F. A. G. Massuger ◽  
...  
2021 ◽  
Vol 5 (7) ◽  
pp. 691-694
Author(s):  
Özlem HELVACİOGLU ◽  
Zeynep TOPKARCI ◽  
Çağlar HELVACIOĞLU ◽  
Ayşe KAVAK

Doctor Ru ◽  
2021 ◽  
Vol 20 (6) ◽  
pp. 102-106
Author(s):  
N.I. Chernova ◽  
◽  
I.S. Zadorozhnaya ◽  

Study Objective: To assess the therapeutic efficiency of liposomal gelcoat with dihydroquercetin Flamena in combination therapy of vulvar lichen sclerosus (VLS). Study Design: open comparative perspective study. Materials and Methods. The study included 52 patients with VLS aged 22 to 65 years. Patients were randomised into two therapeutic groups: 27 patients in group 1 had a standard course of therapy with ultrapotent topic glucocorticosteroids (tGCS) for 3 months; 25 patients in group 2 had a standard intermittent 3-month therapy with Flamena gel for 1.5 month. Therapy efficiency was evaluated using the Dermatological Symptom Scale, visual analogue scale, and Dermatological Quality of Life Index (DQoLI). Therapeutic manipulations were assessed during 6 visits. Study Results. Flamena gel facilitated clinical remission maintenance and prolongation. Starting from visit 4, there were differences between group 1 and group 2 values. By visit 5, group 2 patients demonstrated stable regression or reduction in white spots and papules/plaques (not more than 0.8 ± 0.35 and 0.5 ± 0.26 points, respectively). At the same time, group 1 had clinical symptoms intensity rising to 1.6 ± 0.87 points (white spots) and 1.2 ± 0.9 points (papules/plaques), correlating with subjective symptoms aggravation. Effects of therapy on DQoLI were demonstrated with reduction in mean values to 4.2 ± 2.6 points (group 1) and 3.2 ± 1.4 points (group 2) by visit 2. In group 2, the values remained at 3.3 ± 0.6 points by day 60 (visit 6) of follow-up, whereas in group 1 the VLS impact over quality of life increased from mild (4.2 ± 2.6 points — visit 2) to moderate (7.1 ± 2.3 points — visit 6) in a majority of study subjects. Conclusion. A comparative study demonstrated a marked therapeutic effect and high safety profile of Flamena gel in a combination therapy of VLS patients. It improves disease prognosis due to antiinflammatory, antiseptic and regenerative action, thus allowing reducing the frequency and amount of tGCS use. Keywords: vulvar lichen sclerosus, Flamena gel, vulvar itching


2020 ◽  
Vol 14 (2) ◽  
pp. 203-210
Author(s):  
A. G. Solopova ◽  
E. E. Achkasov ◽  
A. D. Makatsariya ◽  
V. S. Moskvichyova ◽  
A. E. Ivanov

Aim: to assess the psycho-emotional profile in patients with vulvar lichen sclerosus.Materials and methods. We examined 57 patients with a diagnosis of vulvar lichen sclerosus, the average age of 35.0 ± 0.6 (from 18 to 45) years. The control group included 45 healthy women without dystrophic changes in the external genital organs, who applied for a routine examination. The following methods were used to analyze the psycho-emotional profile: WAM questionnaire (well-being, activity, mood), Hospital Anxiety and Depression Scale (HADS), the Dermatology Life Quality Index (DLQI).Results. In patients with vulvar lichen sclerosus a decrease in indicators “well-being” (24.3 ± 1.7 versus 52.4 ± 5.6 scores) and “mood” (28.7 ± 3.6 versus 58.1 ± 6.1 scores) was revealed; “activity” was changed slightly (41.2 ± 3.2 against 47.4 ± 4.9 scores). Depressive (75.4 % versus 15.6 %) and anxiety (68.4 % versus 20 %) disorders were also more common in this group. Significant deterioration in the quality of life in patients was confirmed by a DIQL (18.79 ± 4.98 scores).Conclusion. Psycho-emotional profile of patients with vulvar lichen sclerosus is characterized by a change in most of the analyzed parameters. The presence of anxiety-depressive disorders can aggravate both the general somatic state and the course of the underlying disease. So activities aimed at improving the quality of life should be included in the rehabilitation of these patients.


JAMA ◽  
2004 ◽  
Vol 291 (12) ◽  
pp. 1447 ◽  
Author(s):  
Miriam Kuppermann ◽  
R. Edward Varner ◽  
Robert L. Summitt, Jr ◽  
Lee A. Learman ◽  
Christine Ireland ◽  
...  

2020 ◽  
Vol 10 (9) ◽  
pp. 57
Author(s):  
Masadza Wezzie ◽  
Siankulu Elaine ◽  
Kawalika Micheal ◽  
Victoria Mwiinga-Kalusopa ◽  
Patricia Katowa-Mukwato

Background: Breast cancer is the most frequently diagnosed malignancy among women in the world with an estimation of 1.67 million new diagnoses worldwide in 2012 estimated at 25% of all cancers. In Zambia, breast cancer is the second most common cancer affecting women and accounts for 9% of all histologically proven cancers among patients admitted at the country’s only Cancer Diseases Hospital Most of the patients receive multiple treatment modalities; Surgery, Chemotherapy, Radiation Therapy and Hormonal Therapy, each with its own long-term side effects with a potential to affect  the women’s functionality, self-image and sexuality consequently the general quality of life of these women.Methods: A descriptive cross-sectional study design was used to investigate the Quality of Life (QoL) and factors influencing QoL among women with breast cancer receiving care at Zambia’s only Cancer Diseases Hospital. A total of 130 breast cancer patients on treatment who were willing to participate in the study were selected using simple random sampling. Data was collected using the European Organization for Research and Treatment in Cancer Quality of Life Questionnaire (EORTCQLQ–C30) and its breast cancer supplementary measure (QLQ-BR23). The tool assessed QoL across the physical, role, cognitive, emotional, and social functioning and sexual function domains.Results: Overall, just about half (52.5%) of the 130 respondents had high Quality of Life. QoL which was measured by the EORTCQLQ–C30 under the five domains (Physical, role, emotional, cognitive and sexual functioning) was high in four out of the five which scored above the global mean score of 68. Only the emotional functioning domain scored (65) below the mean. Conversely, the symptom scale scored high on all the eight sub items of fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea which signified high symptom experience among respondents. Similarly using the breast cancer supplementary measure (QLQ-BR23), two out of the four functional subscales (body image and sexual functioning) score high than average while sexual enjoyment and future perspectives score low. On the symptom scale, three out of the four scales scored higher than averages, signifying high symptom experience. Demographic characteristics which had significant association with QoL were age (p < .023), level of education (p < .023) and financial status (p < .000). Other factors that had significant association with QoL were type of treatment being received (p < .023), the severity of condition (p < .000), access to health care services (p < .000) and social support (p < .000).Conclusions: A diagnosis of breast cancer and its subsequent treatment affects several facets of a woman’s life ranging from physical, emotional, social and financial aspects consequently affecting the entire QoL. However the QoL varies and is influenced by a number of factors including age at diagnosis of cancer, level of education, financial status, type of treatment received, severity of the condition, access to health care facilities and social support. Therefore any intervention aimed at improving the QoL should be multidimensional.


Sign in / Sign up

Export Citation Format

Share Document